Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were sinking 9.5% lower as of 11:27 a.m. ET on Thursday after falling as much as 12.6% earlier in the day. The sell-off came after the drugmaker announced its fourth-quarter and full-year 2023 results.

Alnylam reported Q4 total revenue of $439.7 million, up 31% year over year. This result came in a little below the average analysts' estimate of $442.9 million.

The company posted a net loss in Q4 of $137.9 million, or $1.10 per share, based on generally accepted accounting principles (GAAP). Alnylam's non-GAAP net loss was $96.6 million, or $0.77 per share. The consensus Wall Street estimate was for a net loss of $1.32 per share.

Continue reading

Source Fool.com